Dissecting the Specificity of Adenosyl Sulfamate Inhibitors Targeting the Ubiquitin-Activating Enzyme

Structure

Volumn 25, Issue 7, 2017, Pages 1120-1129.e3

  Misra, Mohit ^a,b   Kuhn, Maximilian ^b   Löbel, Mark ^a   An, Heeseon ^c   Statsyuk, Alexander V ^c,d   Sotriffer, Christoph ^b   Schindelin, Hermann ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF HOUSTON   (United States)

Author keywords

adenosyl sulfamate inhibitors; cancer; drug design; E1 enzymes; ubiquitin; ubiquitin activating enzyme; ubiquitin like protein

Indexed keywords

ABPA 3; ADENOSYL SULFAMATE INHIBITOR; LIGASE INHIBITOR; MLN 7243; PEVONEDISTAT; UBIQUITIN E1; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; CYCLOPENTANE DERIVATIVE; ENZYME INHIBITOR; MLN7243; NUCLEOSIDE; PROTEIN BINDING; PYRIMIDINE DERIVATIVE; SACCHAROMYCES CEREVISIAE PROTEIN; SULFONAMIDE; UBE1 PROTEIN, HUMAN;

ADENYLATION; ARTICLE; COVALENT BOND; CRYSTAL STRUCTURE; DNA ADDUCT; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG TARGETING; GENE MUTATION; IN VITRO STUDY; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; YEAST; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; ENZYME SPECIFICITY; GENETICS; HUMAN; METABOLISM; MUTATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

BINDING SITES; CYCLOPENTANES; ENZYME INHIBITORS; HUMANS; MUTATION; NUCLEOSIDES; PROTEIN BINDING; PYRIMIDINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SACCHAROMYCES CEREVISIAE PROTEINS; SUBSTRATE SPECIFICITY; SULFONAMIDES; UBIQUITIN-ACTIVATING ENZYMES;

EID: 85020090314     PISSN: 09692126     EISSN: 18784186     Source Type: Journal    
DOI: 10.1016/j.str.2017.05.001     Document Type: Article

References (56)

1. Adams, P.D., Afonine, P.V., Bunkoczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J., Hung, L.W., Kapral, G.J., Grosse-Kunstleve, R.W., et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66 (2010), 213–221.
2. An, H., Statsyuk, A.V., Development of activity-based probes for ubiquitin and ubiquitin-like protein signaling pathways. J. Am. Chem. Soc. 135 (2013), 16948–16962.
3. An, H., Statsyuk, A.V., An inhibitor of ubiquitin conjugation and aggresome formation. Chem. Sci. 6 (2015), 5235–5245.
4. An, H., Statsyuk, A.V., Facile synthesis of covalent probes to capture enzymatic intermediates during E1 enzyme catalysis. Chem. Commun. (Camb.) 52 (2015), 2477–2480.
5. Åqvist, J., Marelius, J., The linear interaction energy method for predicting ligand binding free energy. Comb. Chem. High Throughput Screen. 4 (2001), 613–626.
6. Bacik, J.P., Walker, J.R., Ali, M., Schimmer, A.D., Dhe-Paganon, S., Crystal structure of the human ubiquitin-activating enzyme 5 (UBA5) bound to ATP: mechanistic insights into a minimalistic E1 enzyme. J. Biol. Chem. 285 (2010), 20273–20280.
7. de Beer, T.A., Berka, K., Thornton, J.M., Laskowski, R.A., PDBsum additions. Nucleic Acids Res. 42 (2014), D292–D296.
8. Brownell, J.E., Sintchak, M.D., Gavin, J.M., Liao, H., Bruzzese, F.J., Bump, N.J., Soucy, T.A., Milhollen, M.A., Yang, X., Burkhardt, A.L., et al. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol. Cell 37 (2010), 102–111.
9. Burch, T.J., Haas, A.L., Site-directed mutagenesis of ubiquitin. Differential roles for arginine in the interaction with ubiquitin-activating enzyme. Biochemistry 33 (1994), 7300–7308.
10. Cappadocia, L., Lima, C.D., Ubiquitin-like protein conjugation: structures, chemistry, and mechanism. Chem. Rev., 2017, 10.1021/acs.chemrev.6b00737.
11. Case, D.A., Babin, V., Berryman, J.T., Betz, R.M., Cai, Q., Cerutti, D.S., Cheatham, T.E. III, Darden, T.A., Duke, R.E., Gohlke, H., et al. AMBER 14. 2014, University of California, San Francisco.
12. Chen, J.J., Tsu, C.A., Gavin, J.M., Milhollen, M.A., Bruzzese, F.J., Mallender, W.D., Sintchak, M.D., Bump, N.J., Yang, X., Ma, J., et al. Mechanistic studies of substrate-assisted inhibition of ubiquitin-activating enzyme by adenosine sulfamate analogues. J. Biol. Chem. 286 (2011), 40867–40877.
13. Correale, S., de Paola, I., Morgillo, C.M., Federico, A., Zaccaro, L., Pallante, P., Galeone, A., Fusco, A., Pedone, E., Luque, F.J., Catalanotti, B., Structural model of the hUbA1-UbcH10 quaternary complex: in silico and experimental analysis of the protein-protein interactions between E1, E2 and ubiquitin. PLoS One, 9, 2014, e112082.
14. Darden, T., York, D., Pedersen, L., Particle mesh Ewald: an N ⋅ log(N) method for Ewald sums in large systems. J. Chem. Phys. 98 (1993), 10089–10092.
15. Emsley, P., Lohkamp, B., Scott, W.G., Cowtan, K., Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66 (2010), 486–501.
16. Frisch, M.J., Trucks, G.W., Schlegel, H.B., Scuseria, G.E., Robb, M.A., Cheeseman, J.R., Scalmani, G., Barone, V., Mennucci, B., Petersson, G.A., et al. Gaussian 09, Revision A.02. 2009, Gaussian, Inc.
17. Haas, A.L., Warms, J.V., Rose, I.A., Ubiquitin adenylate: structure and role in ubiquitin activation. Biochemistry 22 (1983), 4388–4394.
18. Hershko, A., Ciechanover, A., The ubiquitin system. Annu. Rev. Biochem. 67 (1998), 425–479.
19. Hornak, V., Abel, R., Okur, A., Strockbine, B., Roitberg, A., Simmerling, C., Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 65 (2006), 712–725.
20. Huang, D.T., Hunt, H.W., Zhuang, M., Ohi, M.D., Holton, J.M., Schulman, B.A., Basis for a ubiquitin-like protein thioester switch toggling E1-E2 affinity. Nature 445 (2007), 394–398.
21. Jorgensen, W.L., Chandrasekhar, J., Madura, J.D., Impey, R.W., Klein, M.L., Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 79 (1983), 926–935.
22. Kabsch, W., XDS. Acta Crystallogr. D Biol. Crystallogr. 66 (2010), 125–132.
23. Kessler, J.D., Kahle, K.T., Sun, T.T., Meerbrey, K.L., Schlabach, M.R., Schmitt, E.M., Skinner, S.O., Xu, Q.K., Li, M.Z., Hartman, Z.C., et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 335 (2012), 348–353.
24. Knight, Z.A., Shokat, K.M., Features of selective kinase inhibitors. Chem. Biol. 12 (2005), 621–637.
25. Labute, P., Protonate3D: assignment of ionization states and hydrogen coordinates to macromolecular structures. Proteins 75 (2009), 187–205.
26. Lee, I., Schindelin, H., Structural insights into E1-catalyzed ubiquitin activation and transfer to conjugating enzymes. Cell 134 (2008), 268–278.
27. Lois, L.M., Lima, C.D., Structures of the SUMO E1 provide mechanistic insights into SUMO activation and E2 recruitment to E1. EMBO J. 24 (2005), 439–451.
28. Lu, X., Olsen, S.K., Capili, A.D., Cisar, J.S., Lima, C.D., Tan, D.S., Designed semisynthetic protein inhibitors of Ub/Ubl E1 activating enzymes. J. Am. Chem. Soc. 132 (2010), 1748–1749.
29. McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., Read, R.J., Phaser crystallographic software. J. Appl. Crystallogr. 40 (2007), 658–674.
30. Milhollen, M.A., Thomas, M.P., Narayanan, U., Traore, T., Riceberg, J., Amidon, B.S., Bence, N.F., Bolen, J.B., Brownell, J., Dick, L.R., et al. Treatment-emergent mutations in NAEβ confer resistance to the NEDD8-activating enzyme inhibitor MLN4924. Cancer Cell 21 (2012), 388–401.
31. Milletti, F., Storchi, L., Sforna, G., Cruciani, G., New and original pKa prediction method using grid molecular interaction fields. J. Chem. Inf. Model. 47 (2007), 2172–2181.
32. Mueller, U., Forster, R., Hellmig, M., Huschmann, F.U., Kastner, A., Malecki, P., Puhringer, S., Rower, M., Sparta, K., Steffien, M., et al. The macromolecular crystallography beamlines at BESSY II of the Helmholtz-Zentrum Berlin: current status and perspectives. Eur. Phys. J. Plus, 130, 2015, 141.
33. Murshudov, G.N., Vagin, A.A., Dodson, E.J., Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53 (1997), 240–255.
34. Nawrocki, S.T., Griffin, P., Kelly, K.R., Carew, J.S., MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy. Expert Opin. Investig. Drugs 21 (2012), 1563–1573.
35. Noda, N.N., Satoo, K., Fujioka, Y., Kumeta, H., Ogura, K., Nakatogawa, H., Ohsumi, Y., Inagaki, F., Structural basis of Atg8 activation by a homodimeric E1, Atg7. Mol. Cell 44 (2011), 462–475.
36. Olsen, S.K., Capili, A.D., Lu, X., Tan, D.S., Lima, C.D., Active site remodelling accompanies thioester bond formation in the SUMO E1. Nature 463 (2010), 906–912.
37. Oweis, W., Padala, P., Hassouna, F., Cohen-Kfir, E., Gibbs, D.R., Todd, E.A., Berndsen, C.E., Wiener, R., Trans-binding mechanism of ubiquitin-like protein activation revealed by a UBA5-UFM1 complex. Cell Rep. 16 (2016), 3113–3120.
38. Phillips, J., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., Chipot, C., Skeel, R., Kalé, L., Schulten, K., Scalable molecular dynamics with NAMD. J. Comput. Chem. 26 (2005), 1781–1802.
39. Robert, X., Gouet, P., Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res. 42 (2014), W320–W324.
40. Roe, D.R., Cheatham, T.E. III, PTRAJ and cpptraj: software for processing and analysis of molecular dynamics trajectory data. J. Chem. Theor. Comput 9 (2013), 3084–3095.
41. Sarantopoulos, J., Shapiro, G.I., Cohen, R.B., Clark, J.W., Kauh, J.S., Weiss, G.J., Cleary, J.M., Mahalingam, D., Pickard, M.D., Faessel, H.M., et al. Phase I study of the investigational NEDD8-activating enzyme inhibitor Pevonedistat (TAK- 924/MLN4924) in patients with advanced solid tumors. Clin. Cancer Res. 22 (2016), 847–857.
42. Schäfer, A., Kuhn, M., Schindelin, H., Structure of the ubiquitin-activating enzyme loaded with two ubiquitin molecules. Acta Crystallogr. D Biol. Crystallogr. 70 (2014), 1311–1320.
43. Schulman, B.A., Harper, J.W., Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways. Nat. Rev. Mol. Cell Biol. 10 (2009), 319–331.
44. Shah, J.J., Jakubowiak, A.J., O'Connor, O.A., Orlowski, R.Z., Harvey, R.D., Smith, M.R., Lebovic, D., Diefenbach, C., Kelly, K., Hua, Z., et al. Phase I study of the novel investigational NEDD8-activating enzyme inhibitor Pevonedistat (MLN4924) in patients with relapsed/refractory multiple myeloma or lymphoma. Clin. Cancer Res. 22 (2016), 34–43.
45. da Silva, S.R., Paiva, S.L., Lukkarila, J.L., Gunning, P.T., Exploring a new frontier in cancer treatment: targeting the ubiquitin and ubiquitin-like activating enzymes. J. Med. Chem. 56 (2013), 2165–2177.
46. Soucy, T.A., Smith, P.G., Milhollen, M.A., Berger, A.J., Gavin, J.M., Adhikari, S., Brownell, J.E., Burke, K.E., Cardin, D.P., Critchley, S., et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458 (2009), 732–736.
47. St Jean, D.J. Jr., Fotsch, C., Mitigating heterocycle metabolism in drug discovery. J. Med. Chem. 55 (2012), 6002–6020.
48. Streich, F.C. Jr., Haas, A.L., Activation of ubiquitin and ubiquitin-like proteins. Subcell Biochem. 54 (2010), 1–16.
49. Toth, J.I., Yang, L., Dahl, R., Petroski, M.D., A gatekeeper residue for NEDD8-activating enzyme inhibition by MLN4924. Cell Rep. 1 (2012), 309–316.
50. Traore, T., Huck, J.H., Shi, J.S., Sappal, D.S., Duffey, J.D., Yang, Y.Y., Kadakia, E.K., Chakravarty, A.C., Stringer, B.S., Ishii, Y.I., et al. Pre-clinical in vivo characterization of MLN7243, an investigational ubiquitin activating enzyme inhibitor, in solid tumor models. Eur. J. Cancer, 50, 2014, 85.
51. Tsui, V., Case, D.A., Theory and applications of the generalized Born solvation model in macromolecular simulations. Biopolymers 56 (2001), 275–291.
52. Wang, J., Wolf, R.M., Caldwell, J.W., Kollman, P.A., Case, D.A., Development and testing of a general AMBER force field. J. Comput. Chem. 25 (2004), 1157–1174.
53. Wang, J., Wang, W., Kollman, P.A., Case, D.A., Automatic atom type and bond type perception in molecular mechanical calculations. J. Mol. Graph. Model. 25 (2006), 247–260.
54. Wilkinson, K.D., Smith, S.E., O'Connor, L., Sternberg, E., Taggart, J.J., Berges, D.A., Butt, T., A specific inhibitor of the ubiquitin activating enzyme: synthesis and characterization of adenosyl-phospho-ubiquitinol, a nonhydrolyzable ubiquitin adenylate analogue. Biochemistry 29 (1990), 7373–7380.
55. Winn, M.D., Ballard, C.C., Cowtan, K.D., Dodson, E.J., Emsley, P., Evans, P.R., Keegan, R.M., Krissinel, E.B., Leslie, A.G., McCoy, A., et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67 (2011), 235–242.
56. Xu, G.W., Ali, M., Wood, T.E., Wong, D., Maclean, N., Wang, X., Gronda, M., Skrtic, M., Li, X., Hurren, R., et al. The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood 115 (2010), 2251–2259.